MB-CART20.1 Lymphoma

Inclusion Criteria: * Refractory/relapsed CD20+ B-NHL (including malignant transformation like Richter's transformation) with no curative treatment option. * At least 18 years of age * Estimated life expectancy of more than 3 months * ECOG performance status (Eastern cooperative oncology group) of 0-2 * Negative serological HBV (Hepatitis B virus) test, negative testing of HCVAb (Hepatitis C virus Antibody), negative HIV1/2 (Human immunodeficiency virus 1/2 ) test within 6 weeks prior to enrollment * No childbearing potential or negative pregnancy test at screening and before chemotherapy in women with childbearing potential. * Signed and dated informed consent before conduct of any trial-specific procedure Exclusion Criteria: * Participation in another interventional trial that could interact with this trial * Any evidence 0f CNS (Central nervous system) involvement * Known history or presence of clinically relevant CNS pathology * Patients with history of primary immunodeficiency, * Patients with any history of auto-immune induced condition such as those caused by checkpoint inhibitors, MEK inhibitors or BRAF inhibitors, for example pituitary hypophysitis must be excluded * Patients with Chronic Lymphocytic Leukemia unless suffering from malignant transformation * Active systemic fungal, viral or bacterial infection * Serious cardiac functional incapacity (class III or IV as defined by the New York Heart Association Classification) * Severe pulmonary disease (DLCO (Trans…